<DOC>
	<DOCNO>NCT01936454</DOCNO>
	<brief_summary>A cohort study Evaluate contraceptive effectiveness Sino-implant ( II ) 3rd 4th year use Chinese woman</brief_summary>
	<brief_title>Contraceptive Effectiveness Sino-implant ( II ) China</brief_title>
	<detailed_description>A Study Evaluate Contraceptive Effectiveness Third , Fourth Fifth Year Sino-implant ( II ) Use Pharmacokinetics ( PK ) Five Years use Chinese Women Population : A total 590 Chinese Sino-Implant ( II ) user 20and 44 year age enrol one four prospective cohort : Cohort 1 : n=20 woman insertion date 3-5months prior enrollment follow 2-6 month Cohort 2 : n=20 woman insertion date 9-11 month prior enrollment follow 2-6 month Cohort 3 : n=250 woman insertion date 21-24 month prior enrollment follow month 36 Cohort 4 : n=300 woman insertion date 33-36 month prior enrollment follow month 6 Study Duration : 33 total month field : 3 month participant recruitment ( cohort ) ; 27 month pregnancy monitor PK blood sample Cohort 4 ( 15 month Cohort 3 6 month Cohort 1 Cohort 2 ) ; 3 month close-out activity . For secondary PK outcome , blood sample take 2 6 month apart woman Cohort 1 Cohort 2 ; enrollment , month 30 month 36 first 20 consent woman Cohort 3 ; enrollment month 42 , 48 , 54 , 60 first 30 consent woman Cohort 4 . Primary Objective : To evaluate contraceptive effectiveness Sino-implant ( II ) third fourth year use Secondary Objectives : 1 . To evaluate contraceptive effectiveness Sino-implant ( II ) fifth year use . 2 . To characterize total free levonorgestrel ( LNG ) plasma concentration-time profile five year follow Sino-implant ( II ) insertion 3 . To characterize sex hormone bind globulin ( SHBG ) serum concentration-time profile relationship total LNG level five year follow Sino-implant ( II ) insertion</detailed_description>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Have confirm Sinoimplant ( II ) set place ; Have confirm contraceptive implant insertion date consistent criterion cohort enrol ; Be age 20 44 year , inclusive ; Not wish become pregnant next year ; No desire get implant removal within next year ; Be able understand information give make personal decision whether participate study ; Consent participation sign inform consent form ; Agree able return clinic followup visit ( ) . Acute liver disease cirrhosis selfreport ; Benign malignant tumor liver selfreport ; Use rifampicin , and/or anticonvulsant ( barbiturate , phenytoin , phenobarbital , carbamazepine , oxcarbazepine , primidone , topiramate ) , and/or herbal product contain St. John 's wort ( Hypericum perforatum ) selfreport ; 7 Use medication contain LNG hormone impact LNG SHBG disposition , e.g . treatment LNG oral contraceptive bleed disturbance selfreport ; Known HIVpositive status selfreport ; Any condition ( social medical ) opinion Investigator would make study participation unsafe , would interfere adherence study requirement , complicate data interpretation .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>